Flixonase sprej za nos, suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

flixonase sprej za nos, suspenzija

glaxosmithkline trading services limited, 12 riverwalk, citywest business campus, dublin 24, irska - flutikazonpropionat - sprej za nos, suspenzija - 500 µg/1 g suspenzije, 50 µg/1 inhalacijska doza - urbroj: 1 g suspenzije sadrži 500 mikrograma flutikazonpropionata 1 inhalacijska doza sadrži 50 mikrograma flutikazonpropionata

Sitagliptin / Metformin hydrochloride Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vildagliptin / Metformin hydrochloride Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Sitagliptin / Metformin hydrochloride Sun Europska Unija - hrvatski - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Dercome Clear 40 mg/g suspenzija za kožu Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dercome clear 40 mg/g suspenzija za kožu

dr. august wolff gmbh & co. kg arzneimittel, sudbrackstrasse 56, bielefeld, njemačka - benzoilperoksid, s vodom - suspenzija za kožu - 40 mg/g - urbroj: 100 g suspenzije sadržava 5,33 g benzoilperoksida, s vodom (što odgovara 4,0 g benzoilperoksida)

Flosteron 7 mg/ml suspenzija za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

flosteron 7 mg/ml suspenzija za injekciju

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - natrijev betametazonfosfat betametazondipropionat - suspenzija za injekciju - 2 mg+5 mg/1 ml - urbroj: 1 ml suspenzije za injekciju (1 ampula) sadrži 2 mg betametazona u obliku natrijevog betametazonfosfata i 5 mg betametazona u obliku betametazondipropionata

Kenalog 40 mg/ml suspenzija za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

kenalog 40 mg/ml suspenzija za injekciju

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - triamcinolonacetonid - suspenzija za injekciju - 40 mg/ml - urbroj: 1 ml suspenzije za injekciju (1 ampula) sadrži 40 mg triamcinolonacetonida

Lutetium (177Lu) chloride Billev (previously Illuzyce) Europska Unija - hrvatski - EMA (European Medicines Agency)

lutetium (177lu) chloride billev (previously illuzyce)

billev pharma aps - lutetium (177lu) chloride - radionuklidno slikanje - terapeutski radiofarmaceutski pripravci - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Sitagliptin / Metformin hydrochloride Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. trostruki kombinovanu terapiju) kao dodatak prehrani i vježbe kod pacijenata, nedovoljno kontroliranim o njihovo maksimalno переносимой doze метформина i sulfonilurejom. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Curosurf 120 mg/1,5 ml ukapna tekućina za dušnik i pluća, suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

curosurf 120 mg/1,5 ml ukapna tekućina za dušnik i pluća, suspenzija

chiesi pharmaceuticals gmbh, gonzagagasse 16/16, beč, austrija - fosfolipidna frakcija od svinjskih pluća - ukapna tekućina za dušnik i pluća, suspenzija - 120 mg/1,5 ml - urbroj: 1 bočica od 1,5 ml sadrži 120 mg fosfolipidne frakcije iz svinjskih pluća (poraktant alfa). 1 ml suspenzije: 80 mg/ml fosfolipidne frakcije iz svinjskih pluća (poraktant alfa), što odgovara približno 74 mg/ml ukupnih fosfolipida i 0,9 mg/ml hidrofobnih bjelančevina male molekulske mase